VKORC1和CYP2C9基因多态性对华法林抗凝初期维持剂量及剂量波动的影响

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (839 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of VKORC1 and CYP2C9 gene polymorphism on the lasting dose and dose fluctuation of warfarin at the initial anticoagulation phase (90 d after administration). Methods A total of 201 patients who underwent mechanical heart valve replacement in the First Affiliated Hospital, Sun Yat-sen University from June 2014 to December 2016 were recruited. The genotypes of VKORC1 rs7294 and CYP2C9*3 were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The effects of VKORC1 and CYP2C9 genotypes on daily warfarin lasting dose (LD) and daily warfarin dose difference (DD) were analyzed. Results The mutation frequency of VKORC1 rs7294 C＞T and CYP2C9*3 was 12.5% and 2.5%, respectively, meeting the hardy weinberg equilibrium. There was no significant effect of CYP2C9*3 on LD and DD （P ＞ 0.05）. LD and DD of VKORC1 rs7294 T mutant carriers were significantly higher than that of CC wild homozygous carriers (P ＜ 0.001,P ＜ 0.01). Conclusion The mutation of VKORC1 rs7294 C＞T leads to the increase of warfarin anticoagulant lasting dose required by patients, which is more likely to cause dose fluctuation. Therefore, the monitoring of international standardized ratio should be strengthened.

Key words： Warfarin VKORC1 CYP2C9 Gene polymorphism Dose volatility Mechanical heart valve replacement

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Shuyu1
	2 XU Zhe3 ZHOU Shouning2 ZHENG Zhuoling2 TANG Shifan2 ZHANG Xi3 HUANG Min2 LI Jiali2

Cite this article:

ZHANG Shuyu1,2 XU Zhe3 ZHOU Shouning2 ZHENG Zhuoling2 TANG Shifan2 ZHANG Xi3 HUANG Min2 LI Jiali2. Effect of VKORC1 and CYP2C9 gene polymorphism on the lasting dose and dose fluctuation at the initial anticoagulation phase[J]. 中国医药导报, 2019, 16(31): 34-36,45.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I31/34

[1] Rishavy MA，Hallgren KW，Wilson L，et al. Warfarin alters vitamin K metabolism：a surprising mechanism of VKORC1 uncoupling necessitates an additional reductase [J]. Blood，2018，131（25）：2826-2835.
[2] Johnson JA，Cavallari LH. Warfarin pharmacogenetics [J]. Trends Cardiovasc Med，2015，25（1）：33-41.
[3] Vestergaard AS，Skj?覬th，F，Larsen TB，et al. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation：A systematic review and meta-regression analysis [J]. PLoS One，2017，12（11）：e0188482.
[4] Liu J，Jiang HH，Wu DK，et al. Effect of gene polymorphims on the warfarin treatment at initial stage [J]. Pharmacogenomics J， 2017，17（1）：47-52.
[5] Tavares LC，Marcatto LR，Santos PCJL. Genotype-guided warfarin therapy：Current status [J]. Pharmacogenomics，2018， 19（7）：667-685.
[6] Kaye JB，Schultz LE，Steiner HE，et al. Warfarin Pharmacogenomics in Diverse Populations [J]. Pharmacotherapy，2017，37（9）：1150-1163.
[7] Zhang J，Chen Z， Chen C. Impact of CYP2C9，VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients：A systematic review and meta-analysis [J]. Meta Gene，2016，9：197-209.
[8] 胡蓉，许哲，赵立子，等.POR基因多态性与华法林维持剂量关系的研究[J].中国药理学通报，2014，（5）：706-710.
[9] Cen HJ，Zeng WT，Leng XY，et al. CYP4F2 rs2108622：a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement [J]. Br J Clin Pharmacol，2010，70（2）：234-240.
[10] Hadjipanagi D，Chrysanthou S，Voskarides K，et al. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1，CYP2C9 and CYP3A5 in the Greek-Cypriot population [J]. BMC Res Notes，2014，7：123.
[11] Turgut Cosan D，Yazici HU，Colak E，et al. Susceptiveness of Vitamin K epOxide Reductase Complex Subunit 1 Gene Polymorphism in Essential Hypertension [J]. Genet Test Mol Biomarkers，2017，21（5）：292-297.
[12] Wen MS，Chang KC，Lee TH，et al. Pharmacogenetic dosing of warfarin in the Han-Chinese population：a randomized trial [J]. Pharmacogenomics，2017，18（5）：245-253.
[13] Shi C，Yan W，Wang G，et al. Pharmacogenetics-Based versus Conventional Dosing of Warfarin：A Meta-Analysis of Randomized Controlled Trials [J]. PLoS One，2015， 10（12）：e0144511.
[14] Xu Z，Zhang SY，Huang M，et al. Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves：A Randomized Controlled Trial [J]. Ann Thorac Surg，2018， 106（6）：1774-1781.
[15] Shaik AN，Bohnert T，Williams DA，et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins [J]. J Pharm Sci，2016，105（6）：1976-1986.
[16] Jia L，Wang Z，Men J，et al. Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population [J]. Ther Clin Risk Manag，2017，13：421-425.
[17] Wypasek E，Mazur P，Bochenek M，et al. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up [J]. J Physiol Pharmacol，2016， 67（3）：385-393.
[18] Wang LS，Shang JJ，Shi SY，et al. Influence of ORM1 polymorphisms on the maintenance stable warfarin dosage [J]. Eur J Clin Pharmacol，2013，69：1113-1120.
[19] Chen J，Shao L，Gong L，et al. A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients[J]. PLoS One，2014，9（8）：e105250.
[20] Wu S，Chen X，Jin DY，et al. Warfarin and vitamin K epoxide reductase：a molecular accounting for observed inhibition [J]. Blood，2018，132（6）：647-657.